We are live on ! Find out more
AMLX icon

Amylyx Pharmaceuticals
AMLX

171 hedge funds and large institutions have $1.59B invested in Amylyx Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 62 increasing their positions, 53 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

503% more call options, than puts

Call options by funds: $9.02M | Put options by funds: $1.5M

17% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 53

17% more capital invested

Capital invested by funds: $1.36B → $1.59B (+$230M)

1.02% more ownership

Funds ownership: 102.24% → 103.27% (+1%)

4% less funds holding

Funds holding: 179 → 171 (-8)

17% less funds holding in top 10

Funds holding in top 10: 6 → 5 (-1)

19% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 36

Holders
171
Holders Change
-8
Holders Change %
-4.47%
% of All Funds
2.1%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.06%
New
29
Increased
62
Reduced
53
Closed
36
Calls
$9.02M
Puts
$1.5M
Net Calls
+$7.52M
Net Calls Change
+$2.34M

Top Buyers

1
SL
Siren LLC
Connecticut
+$17.3M
2
Franklin Resources
Franklin Resources
California
+$14.9M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$11M
4
Barclays
Barclays
United Kingdom
+$9.52M
5
JAM
Jupiter Asset Management
United Kingdom
+$8.12M

Top Sellers

1
SI
Sofinnova Investments
California
-$6.37M
2
SCM
Silverarc Capital Management
Massachusetts
-$6.12M
3
Ameriprise
Ameriprise
Minnesota
-$6.07M
4
PSC
Patient Square Capital
California
-$4.23M
5
NCM
Nantahala Capital Management
Connecticut
-$4.22M
Name Holding Trade Value Shares
Change 		Change in
Stake
JSAM
151
J. Safra Asset Management
New York
$5.24K +$3.57K +254 +207%
Los Angeles Capital Management
152
Los Angeles Capital Management
California
$4.52K -$7.41K -527 -62%
PNC Financial Services Group
153
PNC Financial Services Group
Pennsylvania
$3.93K -$2.18K -155 -35%
MPWT
154
MassMutual Private Wealth & Trust
Connecticut
$3.92K +$1.81K +129 +84%
PWA
155
Physician Wealth Advisors
Utah
$3.81K – – –
Jones Financial Companies
156
Jones Financial Companies
Missouri
$3.66K +$3.38K +240 +800%
S
157
SignatureFD
Georgia
$3.53K +$3.57K +254 New
LFG
158
Larson Financial Group
Missouri
$2.79K +$2.25K +160 +390%
EB
159
Eastern Bank
Massachusetts
$2.78K +$2.81K +200 New
HI
160
Harbour Investments
Wisconsin
$1.25K – – –
SHIM
161
Stone House Investment Management
Pennsylvania
$1.01K +$1.03K +73 New
RIL
162
Rothschild Investment LLC
Illinois
$765 +$774 +55 New
SIC
163
Salem Investment Counselors
North Carolina
$765 +$774 +55 New
AF
164
Allworth Financial
California
$556 +$394 +28 +233%
CIAM
165
Caitong International Asset Management
Hong Kong
$500 -$53.8K -3,823 -99%
EWA
166
EverSource Wealth Advisors
Alabama
$361 +$14 +1 +4%
FFA
167
Farther Finance Advisors
California
$316 +$28 +2 +10%
EP
168
Essential Partners
California
$209 -$28 -2 -12%
AAS
169
Ameritas Advisory Services
Nebraska
$42 +$42 +3 New
SS
170
SBI Securities
Japan
$14 – – –
SI
171
Sofinnova Investments
California
– -$6.37M -527,099 Closed
SCM
172
Silverarc Capital Management
Massachusetts
– -$6.12M -506,242 Closed
Ameriprise
173
Ameriprise
Minnesota
– -$6.07M -502,366 Closed
PSC
174
Patient Square Capital
California
– -$4.23M -350,000 Closed
Two Sigma Advisers
175
Two Sigma Advisers
New York
– -$3.97M -328,401 Closed
5 6
7
8 9

AMLX Hedge Fund Activity: Q1 2026 in Review

171 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Amylyx Pharmaceuticals (AMLX) for Q1 2026, worth a combined $1.59B — up 17% from $1.36B a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of AMLX and 29 opened new positions — a net loss of 7 holders — while 53 trimmed existing stakes and 62 added.

The largest buyer was Siren LLC, opening a new position worth an estimated $17.3M. The largest seller was Sofinnova Investments, exiting entirely with an estimated $6.37M sold.

  • 171 institutional investors held Amylyx Pharmaceuticals (AMLX) as of Q1 2026, down from 179 in Q4 2025.
  • Funds reported $1.59B of Amylyx Pharmaceuticals stock for Q1 2026, up 17% quarter-over-quarter.
  • 29 funds opened new Amylyx Pharmaceuticals positions in Q1 2026 and 36 closed out, a net change of -7 holders.
  • The largest Amylyx Pharmaceuticals buyer in Q1 2026 was Siren LLC, an estimated $17.3M added.
  • The largest Amylyx Pharmaceuticals seller in Q1 2026 was Sofinnova Investments, an estimated $6.37M sold.

Based on aggregated 13F filings for Q1 2026.